...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another possibility?
Hepa made the deal with RVX not Zenith. But I think that deal highlighted some complication of the RVX Preferred Shares which are owned by Zenith. That's why they made some adjustments to the royalty structure but I'm still fuzzy on the details of those adjustments. The Special Meeting of (RVX) Shareholders on June 30, 2015 document explains it all and I'll have to read it again to try and understand it better. Sorry I don't know how to post the link. I think that that Hepa deal and the spin out of Zenith has given RVX and Zenith good experience in these things which makes me think they may be doing more of them. JMHO PVLee
Share
New Message
Please login to post a reply